Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

Overcoming challenges to cellular starting material collection

Q&A with the Be The Match BioTherapies Collection Network Liaison team

An opportunity to impact the future of medicine

As told by Leah, Be The Match BioTherapies® allogeneic donor

The benefits of a Quality System Audit Program

Accelerate patient access to cell and gene therapies

Developing and managing a strong collection center network

On-demand webinar available

The crucial role in delivering effective cell and gene therapies

How standardization can overcome challenges in apheresis

Q&A With Be The Match BioTherapies Director of Product Development Operations, Dr. Jamie Margolis